INVESTORS & MEDIA

Corporate Governance

Corporate Governance

Date Name Title Type Shares Traded Price
Feb 14, 2012
Director, President & CEO
Director, President & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 234,616 --
Dec 15, 2003
Director, Chief Exec Officer & President
Director, Chief Exec Officer & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 234,616 --
Dec 13, 2013
Director, President & CEO
Director, President & CEO Grant, award or other acquisition pursuant to Rule 16b-3(d) 239,063 --
Dec 14, 2012
Director, EVP CSO Pres Regen Res Labs
Director, EVP CSO Pres Regen Res Labs Grant, award or other acquisition pursuant to Rule 16b-3(d) 239,063 --
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 240,000 $52.03
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 240,000 --
Dec 16, 2014
Director, President & CEO
Director, President & CEO Grant, award or other acquisition pursuant to Rule 16b-3(d) 240,000 --
Dec 16, 2014
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Grant, award or other acquisition pursuant to Rule 16b-3(d) 240,000 --
Dec 19, 2017
Director, President and CSO
Director, President and CSO Bona fide gift 242,150 --
Dec 19, 2017
Director, President and CSO
Director, President and CSO Bona fide gift 242,150 --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

IR Tools